Finerenone : BeyondPrescription Series: Internist Update

In this video, Dr. Jithesh K (MD, MRCP UK, MBA), Senior Consultant Physician in Internal Medicine, Kozhikode, Kerala, presents a complete clinical reference on Finerenone (Kerendia) — the Non-Steroidal Mineralocorticoid Receptor Antagonist (nsMRA) that is transforming the management of Chronic Kidney Disease, Diabetic Nephropathy, and Heart Failure in 2026. This video covers the drug class, mechanism of action, exact lab criteria and potassium thresholds before starting, maximum tolerated doses of common ARBs and ACEi, dosing by eGFR, the full monitoring schedule, Indian brands and costs, and all major trial evidence including FIDELIO-DKD, FIGARO-DKD, the FIDELITY meta-analysis, FINEARTS-HF (FDA approved HFpEF 2025), the CONFIDENCE combination trial with SGLT2 inhibitors, and the brand-new FIND-CKD 2026 trial showing benefit in non-diabetic CKD for the first time. The video concludes with the 4-Pillar approach to T2DM + CKD and where Finerenone fits as the anti-inflammatory and anti-fibrotic pillar alongside RAS blockers, SGLT2 inhibitors, and GLP-1 receptor agonists. Essential viewing for General Physicians, Internists, Nephrologists, Cardiologists, and Diabetologists. Part of the Beyond Prescription Series: Internist Practice Update — No. 01/2026 For medical professionals and CME purposes only. Not a substitute for individualised clinical judgment.